Trial Profile
A Phase 1 Safety and Tolerability Study of Personalized Live, Attenuated, Double-Deleted Listeria Monocytogenes (pLADD) Immunotherapy in Adults With Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Listeria monocytogenes expressing tumour antigens Aduro Biotech (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Aduro BioTech
- 29 Sep 2020 Status changed from active, no longer recruiting to discontinued.
- 25 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Apr 2018 According to an Aduro BioTech media release, additional immunological data from this trial is expected before the end of 2018.